Astrana Health, Inc. Hits New 52-Week High of $50.61

Astrana Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 50.61 on July 1, 2026. This achievement underscores the company's robust performance in the miscellaneous industry, where it has demonstrated a remarkable 26.49% increase over the past year, outpacing the S&P 500's 20.74% return. With a market capitalization of USD 1,362 million, Astrana Health is classified as a small-cap company. The stock's price-to-earnings (P/E) ratio stands at 58.00, reflecting its growth potential. The company has shown impressive financial health, being net-debt free and maintaining a debt-to-equity ratio of 0.79. Additionally, Astrana Health boasts a return on equity of 3.02%, indicating effective management efficiency. The company's net sales have grown at an annual rate of 35.87%, while net profit surged by 140.64%, as reported in its latest results. With institutional holdings at 60.1%, Astrana Health is well-positioned in the market, further solidifying its status as a noteworthy player in its sector.